| 2026-07-02 | 8-K | 10.2 | Registration Rights Agreement, dated as of July 1, 2026, by and among BridgeBio Pharma, Inc. and the Purchasers identified therein. |
|---|
| 2026-07-02 | 8-K | 10.1 | Investment Agreement, dated as of July 1, 2026, by and among BridgeBio Pharma, Inc. and the Purchasers identified therein. |
|---|
| 2026-06-26 | 8-K | 10.1 | BridgeBio Pharma, Inc. Third Amended and Restated 2021 Stock Option and Incentive Plan and form award agreements thereunder |
|---|
| 2026-05-07 | 10-Q | 10.2 | Amendment No. 5 to Consulting Agreement between Frank McCormick and the Registrant, effective as of March 5, 2026. |
|---|
| 2026-05-07 | 10-Q | 10.1 | BridgeBio Pharma, Inc. Amended and Restated 2019 Employee Stock Purchase Plan |
|---|
| 2026-02-24 | 10-K | 10.25 | Amended and Restated Director Compensation Policy. |
|---|
| 2026-02-24 | 10-K | 10.17 | Amendment No. 4 to Consulting Agreement between Frank McCormick and the Registrant, effective as of March 4, 2025. |
|---|
| 2026-02-24 | 10-K | 10.16 | Amendment No. 3 to Consulting Agreement between Frank McCormick and the Registrant, effective as of March 4, 2024. |
|---|
| 2025-08-05 | 10-Q | 10.2 | Registration Rights Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto. |
|---|
| 2025-08-05 | 10-Q | 10.1 | Securities Purchase Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc., and the purchasers party thereto. |
|---|
| 2025-06-23 | 8-K | 10.1 | BridgeBio Pharma, Inc. Second Amended and Restated 2021 Stock Option and Incentive Plan and form award agreements thereunder |
|---|
| 2025-04-29 | 10-Q | 10.1 | Securities Purchase Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc., and the purchasers party thereto. |
|---|
| 2025-02-20 | 10-K | 10.42 | Employment Agreement between BridgeBio Services, Inc. and Thomas Trimarchi, dated October 10, 2024. |
|---|
| 2024-08-21 | 8-K | 10.2 | Amended and Restated Limited Liability Company Agreement of GondolaBio, LLC, dated as of August 16, 2024* |
|---|
| 2024-08-21 | 8-K | 10.1 | Transaction Agreement, dated as of August 16, 2024, by and among BridgeBio Pharma, Inc., Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities Drawdown (Aggregator) LP, Patient Square Bravo Aggregator, LP, SC US/E GROWTH FUND X MANAGEMENT, L.P., SC US/E Venture Fund XVIII Management, L.P., Frazier Life Sciences XI, L.P., Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences Public Overage Fund, L.P., Cormorant Private Healthcare Fund IV, LP, Cormorant Private Healthcare Fund V, LP, Cormorant Global Healthcare Master Fund, LP, Aisling V Bridge Splitter LP, Kumar Haldea Revocable Trust and GondolaBio, LLC.* |
|---|
| 2024-08-01 | 10-Q | 10.2 | Registration Rights Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto. |
|---|
| 2024-08-01 | 10-Q | 10.1 | Securities Purchase Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc., and the purchasers party thereto. |
|---|
| 2024-06-24 | 8-K | 10.1 | 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan |
|---|
| 2024-05-02 | 10-Q | 10.7 | Amendment No. 3 to Consulting Agreement between Frank McCormick and the Registrant, effective as of March 4, 2024. |
|---|
| 2024-05-02 | 10-Q | 10.6 | Amendment No. 3, effective as of March 1, 2024, to Exclusive (Equity) Agreement effective April 10, 2016, by and between Eidos Therapeutics, Inc. and the Board of Trustees of the Leland Stanford Junior University. |
|---|
| 2024-05-02 | 10-Q | 10.5 | Exclusive License Agreement, dated March 1, 2024, by and among Eidos Therapeutics, Inc., BridgeBio International GmbH, BridgeBio Europe B.V., and Bayer Consumer Care AG. |
|---|
| 2024-05-02 | 10-Q | 10.4 | Funding Agreement, dated January 17, 2024, by and among LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.À R.L. as Purchasers, the Registrant and certain subsidiaries of the Registrant as Seller Parties, and Alter Domus (US) LLC as Collateral Agent. |
|---|
| 2024-05-02 | 10-Q | 10.3 | First Amendment to Financing Agreement, dated as of February 12, 2024, by and among the Registrant, the Guarantors party thereto, the Lenders party thereto, and Blue Owl Capital Corporation as Administrative Agent. |
|---|
| 2024-05-02 | 10-Q | 10.2 | Registration Rights Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto. |
|---|
| 2024-02-22 | 10-K | 10.39 | Amendment to Employment Agreement, between BridgeBio Services, Inc. and Brian Stephenson, dated February 21, 2024. |
|---|
| 2024-02-22 | 10-K | 10.31 | Letter Agreement, Amendment #1 thereto, and Amendments to License Agreement between QED Therapeutics, Inc. and Novartis International Pharmaceutical Ltd., dated May 4, 2018, August 7, 2018, September 10, 2020 and March 30, 2022, respectively. |
|---|
| 2023-11-02 | 10-Q | 10.1 | Securities Purchase Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc., and the purchasers party thereto. |
|---|
| 2023-09-25 | 8-K | 10.2 | Registration Rights Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto |
|---|
| 2023-09-25 | 8-K | 10.1 | Securities Purchase Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto |
|---|
| 2023-08-03 | 10-Q | 10.9 | Form of Non-Qualified Stock Option Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan for Board of Directors (2023 Form). |
|---|
| 2023-08-03 | 10-Q | 10.8 | Form of Non-Qualified Stock Option Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (2023 Form). |
|---|
| 2023-08-03 | 10-Q | 10.7 | Form of Restricted Stock Award Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (2023 Form). |
|---|
| 2023-08-03 | 10-Q | 10.6 | Form of Restricted Stock Unit Award Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (2023 Form). |
|---|
| 2023-08-03 | 10-Q | 10.5 | Form of Non-Qualified Stock Option Agreement under BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (2023 Form). |
|---|
| 2023-08-03 | 10-Q | 10.4 | BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan, effective February 10, 2023. |
|---|
| 2023-08-03 | 10-Q | 10.3 | Form of Restricted Stock Unit Award Agreement under BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (2023 Form). |
|---|
| 2023-05-04 | 10-Q | 10.4 | BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan, effective February 10, 2023. |
|---|
| 2023-02-23 | 10-K | 10.33 | Second Amendment to the Loan and Security Agreement, among U.S. Bank Trust Company National Association, a successor to U.S. Bank National Association, in its capacity as Administrative Agent and Collateral Agent, the Lenders party thereto, the Registrant, and certain subsidiaries of the Registrant, dated as of November 30, 2022. |
|---|
| 2023-02-23 | 10-K | 10.18 | Amendment No. 2 to Consulting Agreement between Frank McCormick and the Registrant, effective as of March 3, 2023. |
|---|
| 2023-02-23 | 10-K | 10.17 | Amendment No. 1 to Consulting Agreement between Frank McCormick and the Registrant, effective as of March 3, 2022. |
|---|
| 2023-02-23 | 10-K | 10.16 | Consulting Agreement between Frank McCormick and the Registrant, effective as of January 1, 2021. |
|---|
| 2022-08-04 | 10-Q | 10.2 | First Amendment to Loan and Security Agreement, dated May 12, 2022, among U.S. Bank National Association in its capacity as Administrative Agent and Collateral Agent, the Lenders party thereto, the Registrant, and certain subsidiaries of the Registrant. |
|---|
| 2022-08-04 | 10-Q | 10.1 | License, Development and Commercialization Agreement, dated May 11, 2022, by and among the Registrant, Navire Pharma, Inc. and Bristol-Myers Squibb Company. |
|---|
| 2022-02-25 | 10-K | 10.39 | Loan and Security Agreement, among U.S. Bank National Association in its capacity as Administrative Agent and Collateral Agent, the Lenders party thereto, the Registrant, and certain subsidiaries of the Registrant, dated as of November 17, 2021. |
|---|
| 2022-02-25 | 10-K | 10.30 | Amended and Restated Director Compensation Policy. |
|---|
| 2022-02-25 | 10-K | 10.1 | Amended and Restated 2021 Stock Option and Incentive Plan and forms of award agreements thereunder. |
|---|
| 2021-11-04 | 10-Q | 10.1 | Amended and Restated Employee Stock Purchase Plan |
|---|
| 2021-05-06 | 10-Q | 10.4 | Amended and Restated Employee Stock Purchase Plan |
|---|
| 2021-05-06 | 10-Q | 10.3 | Sixth Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of April 13, 2021 |
|---|
| 2021-02-25 | 10-K | 10.46 | Fifth Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of January 25, 2021. |
|---|
| 2021-02-25 | 10-K | 10.40 | Third Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of March 2, 2020. |
|---|
| 2021-01-29 | 8-K | 10.1 | Form of Confirmation for Capped Call Transactions. |
|---|
| 2021-01-26 | 8-K | 10.1 | Purchase Agreement, dated January 25, 2021, by and among BridgeBio Pharma, Inc. and J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as representatives of the several Initial Purchasers. |
|---|
| 2020-11-05 | 10-Q | 10.3 | Amended and Restated 2019 Employee Stock Purchase Plan, effective December 12, 2019 |
|---|
| 2020-08-11 | 10-Q | 10.1 | Fourth Amendment to Loan and Security Agreement, dated April 27, 2020 |
|---|
| 2020-03-10 | 8-K | 10.1 | Form of Confirmation for Capped Call Transactions. |
|---|
| 2020-03-06 | 8-K | 10.1 | Purchase Agreement, dated March 4, 2020, by and among BridgeBio Pharma, Inc. and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several Initial Purchasers. |
|---|
| 2020-03-03 | 10-K | 10.39 | Director Compensation Policy |
|---|
| 2020-03-03 | 10-K | 10.38 | Offer Letter, between BridgeBio Pharma, Inc. and James C. Momtazee, dated February 23, 2020. |
|---|
| 2020-03-03 | 10-K | 10.33 | Collaboration Agreement, by and between BridgeBio Gene Therapy, LLC and Catalent Maryland, Inc., formerly Paragon Bioservices, Inc., dated December 31, 2019. |
|---|
| 2020-03-03 | 10-K | 10.28 | Consulting Agreement, between Jennifer E. Cook and the Registrant, effective as of October 14, 2019. |
|---|
| 2020-03-03 | 10-K | 10.14A | Fourth Amendment to the Exclusive License Agreement, between The Regents of the University of California and TheRas, Inc., dated December 16, 2019 |
|---|
| 2019-11-19 | 8-K | 10.1 | Loan and Security Agreement dated November 13, 2019 between Eidos Therapeutics, Inc., a partially owned subsidiary of Registrant, as borrower, Silicon Valley Bank and Hercules Capital, Inc., together as lenders. |
|---|
| 2019-11-08 | 10-Q | 10.3 | Offer Letter, between and BridgeBio Services, Inc. and Yi Ching Yau, dated September 9, 2019 |
|---|
| 2019-11-08 | 10-Q | 10.2 | Offer Letter, between BridgeBio Pharma, Inc. and Brian Stolz, dated September 19, 2019 |
|---|
| 2019-11-08 | 10-Q | 10.1 | License Agreement, by and between the Registrant and Alexion Pharma International Operations Unlimited Company, dated September 9, 2019 |
|---|